Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma

Urologic Oncology
Vincent Launay-VacherStéphane Oudard

Abstract

Side effects of antiangiogenic agents are moderate compared with other therapies. The most frequent adverse events are of a renovascular origin and manifest as hypertension (HTN) and thrombotic microangiopathy. To date, data are scanty on the renal tolerance of such drugs regarding renal function as itself, i.e., glomerular filtration rate (GFR). We report on the evolution of GFR in patients receiving antiangiogenic therapy after unilateral nephrectomy for kidney cancer. Data from 73 patients followed in our oncology department for kidney cancer, who had undergone unilateral nephrectomy, and received any antiangiogenic therapy were reviewed. Their GFR was calculated using the aMDRD formula. All patients showed a declining renal function over time (-1.23 and -2.51 mL/min/1.73 m(2) using the slope of the curve or the difference between GFR at baseline and that at the end of treatment, respectively). Among them, patients who were recorded as having HTN before initiation of antiangiogenic therapy showed a higher decrease in their GFR of -13.28 and -12.06 mL/min/1.73 m(2). We recommend that blood pressure should be measured closely in those patients before initiation of antiangiogenic therapy. When HTN is diagnosed, it should be tre...Continue Reading

References

Mar 15, 2006·Kidney International·B R HemmelgarnB F Culleton
Jul 20, 2007·Cancer·Vincent Launay-VacherUNKNOWN Renal Insufficiency and Cancer Medications (IRMA) Study Group
Nov 21, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S OudardR Motzer
Dec 18, 2007·Lancet·Tammy F ChuMing Hui Chen
Apr 4, 2009·Anti-cancer Drugs·Vincent Launay-Vacher, Gilbert Deray

❮ Previous
Next ❯

Citations

Apr 30, 2011·Journal of the National Cancer Institute·Brian I RiniRobert J Motzer
May 1, 2012·Current Oncology Reports·Suzanne R HaymanVesna D Garovic
Aug 1, 2012·Expert Review of Anticancer Therapy·Fable ZustovichPatrizia Farina
Feb 16, 2013·Néphrologie & thérapeutique·Cécile Vigneau, Nathalie Rioux-Leclercq
Mar 5, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V Launay-VacherB Sprangers
Dec 13, 2016·International Journal of Molecular Sciences·Aleksandra Semeniuk-WojtaśStanisław Niemczyk
Jun 18, 2017·Expert Opinion on Therapeutic Patents·Fan-Wei PengLei Shi
Mar 27, 2021·Cancer Chemotherapy and Pharmacology·Łukasz MielczarekAnna M Czarnecka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.